Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huazhi Rougan Granule for Non-alcoholic Simple Fatty Liver
NCT06202456Phase 4Completed
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- May 2020
- Primary completion
- Jun 2022
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of huazhi rougan granule in non-alcoholic fatty liver disease (NAFLD), sponsored by Shandong New Time Pharmaceutical. Primary endpoint: Liver-to-spleen CT ratio at 12 weeks. Started May 2020; status: completed.
02
Drugs
huazhi rougan granule
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06202456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06202456.